Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
Higher levels of viral antigens in the blood correlated with more severe disease.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.